Cargando…

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection

Detalles Bibliográficos
Autores principales:	Chow, Shien, Evans, Manon, Galvis, Victoria, Leach, Rebecca, Keene, Elizabeth, Chan, Kevin, Spencer-Shaw, Andrea, Jonathan, Shanks, Shabalak, Alaaeldin, Thistlethwaite, Fiona, Hawkins, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288767/ http://dx.doi.org/10.1186/2051-1426-2-S3-P89

Ejemplares similares

High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
por: Chow, S., et al.
Publicado: (2016)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
por: Shohdy, Kyrillus S., et al.
Publicado: (2023)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
por: Evans, Manon, et al.
Publicado: (2014)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
por: Chu, Melinda B., et al.
Publicado: (2013)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study
por: Lagan, Jakub, et al.
Publicado: (2022)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Effects of Hd2 in the presence of the photoperiod-insensitive functional allele of Hd1 in rice
por: Zhang, Zhen-Hua, et al.
Publicado: (2016)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

Reactions of H(2), HD, and D(2) with H(2)(+), HD(+), and D(2)(+): Product-Channel Branching Ratios and Simple Models
por: Merkt, Frédéric, et al.
Publicado: (2022)

Disease Burden of Huntington’s Disease (HD) on People Living with HD and Care Partners in Canada
por: Shaw, Eileen, et al.
Publicado: (2022)

Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
por: Pillai, Manon, et al.
Publicado: (2020)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)
por: Saad, Eddy, et al.
Publicado: (2023)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Arabidopsis histone deacetylase HD2A and HD2B regulate seed dormancy by repressing DELAY OF GERMINATION 1
por: Han, Yongtao, et al.
Publicado: (2023)

Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy
por: Schwarzer, Adrian, et al.
Publicado: (2012)

Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
por: Grünwald, V., et al.
Publicado: (2022)

HD2A and HD2C co-regulate drought stress response by modulating stomatal closure and root growth in Arabidopsis
por: Tahir, Muhammad Sufyan, et al.
Publicado: (2022)

Understanding HD Psychosis: An Analysis from the ENROLL-HD Database
por: Jaini, Ashwin, et al.
Publicado: (2020)

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
por: Magdy, A., et al.
Publicado: (2015)

Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib
por: Ferrer, Florent, et al.
Publicado: (2021)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a604s40br6hro5m4spr971alf8